Hilde De Winter

1.8k citations

32 papers · 1.2k indexed · 1 hit paper · h-index 11

Immunology top 5%
Hematology top 5%
Nephrology top 2%
Genetics top 5%
Radiology, Nuclear Medicine and Imaging top 10%

Co-authors: Filip Callewaert Spero R. Cataland Marie Scully Flora Peyvandi Johanna A. Kremer Hovinga Paul Knöbl Ara Metjian Robert K. Zeldin
Topics: Complement system in diseases (15 papers)Renal Diseases and Glomerulopathies (8 papers)Renal Transplantation Outcomes and Treatments (6 papers)
Cited by: Nephrology Immunology Hematology
Journals: New England Journal of Medicine The Journal of Experimental Medicine Blood
Partner nations: United States Belgium United Kingdom

In The Last Decade

Hilde De Winter

27 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura

2019 602 citations Marie Scully, Spero R. Cataland et al. profile →

Peers

Countries citing papers authored by Hilde De Winter

Since Specialization

Citations

This map shows the geographic impact of Hilde De Winter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hilde De Winter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hilde De Winter more than expected).

Fields of papers citing papers by Hilde De Winter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hilde De Winter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hilde De Winter. The network helps show where Hilde De Winter may publish in the future.

Co-authorship network of co-authors of Hilde De Winter

This figure shows the co-authorship network connecting the top 25 collaborators of Hilde De Winter. A scholar is included among the top collaborators of Hilde De Winter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hilde De Winter. Hilde De Winter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MP0621 (cKit x CD16a x CD47), a Multi-Specific Switch-Darpin with Conditional Blockade of CD47 Targeting Hematopoietic Stem Cells: Preclinical Evaluation of a Next-Generation Conditioning Agent for Stem Cell Transplantation 2024 ·Blood ·(unknown),(unknown),(unknown),(unknown),Alison Ribeiro,Anja Schlegel,(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),(unknown),Hilde De Winter,Keith M. Dawson,(unknown),Anne Goubier	1
2	612 Comprehensive biomarker analyses from a phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic DARPin 2024 ·Regular and Young Investigator Award Abstracts ·(unknown),Vaia Stavropoulou,Alison Ribeiro,(unknown),Hilde De Winter,(unknown),Elena Fernández,(unknown),Paul Baverel,Michael T. Stumpp,Michael P. Sanderson,Anne Goubier,Philippe Legenne	1
3	1475 A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors 2022 ·Hilde De Winter,(unknown),Vaia Stavropoulou,(unknown),Paul Baverel,Carlos Gomez‐Roca,Eelke Gort,Neeltje Steeghs,Kyriaki Ioannou,(unknown),(unknown),(unknown),Vladimir Kirkin,Philippe Legenne,Philippe A. Cassier	1
4	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis 2021 ·Blood Advances ·Flora Peyvandi,Spero R. Cataland,Marie Scully,Paul Coppo,Paul Knoebl,Johanna A. Kremer Hovinga,Ara Metjian,Javier de la Rubia,Katerina Pavenski,(unknown),Hilde De Winter,Filip Callewaert	50
5	170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors 2021 ·Annals of Oncology ·Simone Jeger,Oliver Schönborn‐Kellenberger,Hilde De Winter,Neeltje Steeghs,Eelke Gort,Carlos Gomez‐Roca,Vaia Stavropoulou,Rupert Kenefeck,(unknown),Hong Ji,Claire Marchand,Philippe Legenne,Philippe A. Cassier	1
6	INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA 2021 ·Hematology Transfusion and Cell Therapy ·Flora Peyvandi,Spero R. Cataland,Marie Scully,Paul Coppo,Paul Knoebl,Johanna A. Kremer Hovinga,Ara Metjian,Javier de la Rubia,Katerina Pavenski,(unknown),Filip Callewaert,Hilde De Winter	0
7	Narratives of Patients with Fatal Outcomes During the Phase 2 TITAN and Phase 3 HERCULES Studies 2019 ·Blood ·Spero R. Cataland,Marie Scully,Flora Peyvandi,Paul Knoebl,Johanna A. Kremer Hovinga,Paul Coppo,Ara Metjian,Javier de la Rubia,Katerina Pavenski,Hilde De Winter,Filip Callewaert	0
8	Efficacy and safety of open‐label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study 2019 ·Journal of Thrombosis and Haemostasis ·Paul Knoebl,Spero R. Cataland,Flora Peyvandi,Paul Coppo,Marie Scully,Johanna A. Kremer Hovinga,Ara Metjian,Javier de la Rubia,Katerina Pavenski,(unknown),Hilde De Winter,Filip Callewaert	41
9	Clinical pharmacology of caplacizumab for the treatment of patients with acquired thrombotic thrombocytopenic purpura 2019 ·Expert Review of Clinical Pharmacology ·Maria Laura Sargentini‐Maier,(unknown),Claudia Tersteeg,(unknown),Filip Callewaert,Hilde De Winter	45
10	Integrated Efficacy Results from the Phase II and Phase III Studies with Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura 2018 ·Blood ·Flora Peyvandi,Spero R. Cataland,Marie Scully,Paul Coppo,Paul Knöbl,Johanna A. Kremer Hovinga,Ara Metjian,Javier de la Rubia,Katerina Pavenski,(unknown),Filip Callewaert,Hilde De Winter	5
11	Results of the Randomized, Double-Blind, Placebo-Controlled, Phase 3 Hercules Study of Caplacizumab in Patients with Acquired Thrombotic Thrombocytopenic Purpura 2017 ·Blood ·Marie Scully,Spero R. Cataland,Flora Peyvandi,Paul Coppo,Paul Knöbl,Johanna A. Kremer Hovinga,Ara Metjian,Javier de la Rubia,Katerina Pavenski,Filip Callewaert,Debjit Biswas,Hilde De Winter,Robert K. Zeldin	16
12	Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura 2017 ·Journal of Thrombosis and Haemostasis ·Flora Peyvandi,Marie Scully,Johanna A. Kremer Hovinga,Paul Knöbl,Spero R. Cataland,Kristof De Beuf,Filip Callewaert,Hilde De Winter,Robert K. Zeldin	84
13	617 E1 therapeutic vaccination in patients with chronic HCV genotype 1 infection: Results of a 15-month, placebo-controlled trial 2006 ·Journal of Hepatology ·Heiner Wedemeyer,Hans Van Vlierberghe,(unknown),(unknown),Michael Gschwantler,Stefan Zeuzem,Tania Roskams,V. Desmet,(unknown),(unknown),Hilde De Winter,Geert Maertens,Yves Horsmans	1
14	Delayed neutralization of interferon-γ prevents lethality in primate Gram-negative bacteremic shock 2005 ·Critical Care Medicine ·(unknown),Philip A. Efron,Sven K. Tschoeke,(unknown),Hilde De Winter,K Lorré,Lyle L. Moldawer	10
15	Beta-adrenergic stimulation of alveolar liquid clearance: a novel strategy to resolve pulmonary edema after lung transplantation? 2004 ·European Journal of Anaesthesiology ·Arne Neyrinck,Filip Rega,Lucie Fransen,Hilde De Winter,Nicole C.P. Jannis,P Wouters,Geert M. Verleden,Antoon Lerut,Dirk Van Raemdonck	1
16	NIK-dependent RelB Activation Defines a Unique Signaling Pathway for the Development of Vα14i NKT Cells 2003 ·The Journal of Experimental Medicine ·Dirk Elewaut,(unknown),Kirsten J. L. Hammond,Hilde De Winter,Andrew J. Leishman,Stéphane Sidobre,Olga Turovskaya,Theodore I. Prigozy,Lisa Ma,Theresa A. Banks,David Lo,Carl F. Ware,Hilde Cheroutre,Mitchell Kronenberg	102
17	Regulation of mucosal immune responses by recombinant interleukin 10 produced by intestinal epithelial cells in mice 2002 ·Gastroenterology ·Hilde De Winter,Dirk Elewaut,Olga Turovskaya,Margaret E. Huflejt,C. Shimeld,Amy Hagenbaugh,Scott W. Binder,Ichiro Takahashi,Mitchell Kronenberg,Hilde Cheroutre	49
18	Which ABO-matching rule should be the decisive factor in the choice between a highly urgent and an elective patient? 2002 ·Transplant International ·Johan De Meester,(unknown),Hilde De Winter,(unknown),Ludolf Erwin Meester,Michel Dekking,Freerk A. Lootsma,Guido G. Persijn,Ferdinand Mühlbacher	4
19	Membrane Lymphotoxin Is Required for the Development of Different Subpopulations of NK T Cells 2000 ·The Journal of Immunology ·Dirk Elewaut,Laurent Brossay,Sybil M. Santee,Olga V. Naidenko,Nicolas Burdin,Hilde De Winter,Jennifer L. Matsuda,Carl F. Ware,Hilde Cheroutre,Mitchell Kronenberg	55
20	Value of axillary ultrasonography and sonographically guided puncture of axillary nodes: A prospective study in 144 consecutive patients 1997 ·Journal of Clinical Ultrasound ·J. Verbanck,(unknown),Hilde De Winter,(unknown),F. Van Aelst,W Tanghe	74

About Hilde De Winter

Hilde De Winter is a scholar working on Transplantation, Nephrology and Immunology, having authored 32 papers that have together received 1.2k indexed citations. Recurring topics across this work include Complement system in diseases (15 papers), Renal Diseases and Glomerulopathies (8 papers) and Renal Transplantation Outcomes and Treatments (6 papers). The work is most often cited by research in Nephrology (276 citations), Immunology (810 citations) and Hematology (339 citations). Hilde De Winter has collaborated with scholars based in United States, Belgium and United Kingdom. Frequent co-authors include Filip Callewaert, Spero R. Cataland, Marie Scully, Flora Peyvandi, Johanna A. Kremer Hovinga, Paul Knöbl, Ara Metjian, Robert K. Zeldin, Javier de la Rubia and Katerina Pavenski. Their work appears in journals such as New England Journal of Medicine, The Journal of Experimental Medicine and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact